Reading VNRX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track VNRX free→Reading VNRX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track VNRX free→QuarterlyIQ Insights · VNRX
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Entry into a Material Definitive Agreement . On June 7, 2026, VolitionRx Limited (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with the purchasers listed on the signature pages thereto (the “Purchasers”), in connection with the Company’s offer of an aggregate of 2,960,000 shares (the “Shares”) of its common stock, par value $0.001 per share (the “Common Stock”), together with accompanying common stock purchase warrants to purchase 1,480,000 shares of…
Entry into a Material Definitive Agreement . As previously reported, VolitionRx Limited (the “Company”) issued to Lind Global Asset Management XII LLC (“Lind”) (i) that certain senior secured convertible promissory note in the original principal amount of $7,500,000 on May 15, 2025 (the “2025 Note”), pursuant to that certain securities purchase agreement, dated May 15, 2025, by and between the Company and Lind, and (ii) that certain senior secured convertible promissory note in the original p…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On May 12, 2026, Mickie Henshall notified the Board of Directors (the “Board”) of VolitionRx Limited (the “Company”) of her decision not to stand for re-election to the Board at the Company’s 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”). Ms. Henshall has served on the Board since August 2022. Ms. Henshall’s decision not to stand…
Results of Operations and Financial Condition. The following information, including Exhibit 99.1, is being “furnished” in accordance with General Instruction B.2. of Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Ac…
Material Modification to Rights of Security Holders. The information set forth in
of the Current Report on Form 8-K filed with the Securities and Exchange Commission on February 9, 2026, VolitionRx Limited (the “Company”) received a notice (the “Notice”) from the NYSE American LLC (the “NYSE American”) indicating that the Company was not in compliance with the NYSE American continued listing standards set forth in Section 1003(a)(i) of the NYSE American Company Guide (the “Company Guide”) requiring a company to have stockholders’ equity of at least $2.0 million if it has r…
Results of Operations and Financial Condition. The following information, including Exhibit 99.1, is being “furnished” in accordance with General Instruction B.2. of Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Ac…
Unregistered Sales of Equity Securities As previously reported, pursuant to that certain securities purchase agreement dated May 15, 2025 (as amended and restated on January 7, 2026, the “ SPA ”), VolitionRx Limited (the “Company”) issued to Lind Global Asset Management XII LLC, a Delaware limited liability company (“ Lind ”), a senior secured convertible promissory note in the principal amount of $7,500,000. In connection with its repayment obligations under such note, (a) on February 17, 20…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing On February 6, 2026, VolitionRx Limited (the “Company”) received a notice (the “Notice”) from the NYSE American LLC (the “NYSE American”) stating that the Company is not in compliance with the NYSE American continued listing standards set forth in Section 1003(a)(i) of the NYSE American Company Guide (the “Company Guide”) requiring a company to have stockholders’ equity of at least $2.0 million…
in its entirety. Based in part upon the representations of Lind in the Amended SPA, the offering and sale of the securities described above was made in reliance on the exemption afforded by Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D under the Securities Act and corresponding provisions of state securities or “blue sky” laws. None of the securities have been registered under the Securities Act or any state securities laws and may not be offered or sold in the United Sta…
Entry into a Material Definitive Agreement. On January 7, 2026, VolitionRx Limited (the “Company”) entered into an amended and restated securities purchase agreement (the “Amended SPA”) with Lind Global Asset Management XII LLC, a Delaware limited liability company (“Lind”). Under the Amended SPA, within ten business days of signing, and subject to the satisfaction of certain closing conditions, we will receive $2,000,000 in funding from Lind in exchange for the issuance to Lind of a Senior S…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On December 5, 2025, Volition Veterinary Diagnostics Development, LLC (“Volition Veterinary”), a majority-owned subsidiary of VolitionRx Limited (the “Company”), provided notice of termination of its employment agreement with Dr. Salvatore Thomas Butera, the Chief Executive Officer of Volition Veterinary, effective as of January 31, 2026 (the “Term…
Entry into a Material Definitive Agreement. As previously reported, on October 10, 2025, the Company entered into an Underwriting Agreement (the “Underwriting Agreement”) with Newbridge Securities Corporation (the “Underwriter”), relating to an underwritten public offering of 11,550,000 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), together with accompanying common stock purchase warrants to purchase up to an aggregate of 11,550,000 shares of Common St…
Results of Operations and Financial Condition. The following information, including Exhibit 99.1, is being “furnished” in accordance with General Instruction B.2. of Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Ac…
Entry into a Material Definitive Agreement. As previously reported, on October 10, 2025, the Company entered into an Underwriting Agreement (the “Underwriting Agreement”) with Newbridge Securities Corporation (the “Underwriter”), relating to an underwritten public offering of 11,550,000 shares (the “Closing Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), together with accompanying common stock purchase warrants to purchase up to an aggregate of 11,550,…
Entry into a Material Definitive Agreement. As previously reported, on October 10, 2025, VolitionRx Limited (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Newbridge Securities Corporation (the “Underwriter”), relating to an underwritten public offering of 11,550,000 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), together with accompanying common stock purchase warrants to purchase up to an aggregate of 11,550,…
Entry into a Material Definitive Agreement. On October 10, 2025, VolitionRx Limited (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Newbridge Securities Corporation (the “Underwriter”), relating to an underwritten public offering of 11,550,000 shares (the “Closing Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), together with accompanying common stock purchase warrants to purchase up to an aggregate of 11,550,0…
of this Current Report on Form 8-K, including the information contained in Exhibits 99.1 and 99.2, shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such a filing. Cautionary Note Regarding Forward-Looking Statements This Current Report contains forwa…
Results of Operations and Financial Condition. On October 10, 2025, the Company disclosed in a prospectus supplement relating to the Offering that, as of September 30, 2025, the Company estimates that it had approximately $0.3 million in cash and cash equivalents. The estimated cash and cash equivalents amount is preliminary and unaudited, represents management’s estimate as of October 10, 2025, is subject to completion of the Company’s financial closing procedures for the three months ended…
Results of Operations and Financial Condition. The following information, including Exhibit 99.1, is being “furnished” in accordance with General Instruction B.2. of Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Ac…
Entry Into a Material Definitive Agreement. On August 1, 2025, VolitionRx Limited, a Delaware corporation (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) with the several purchasers set forth on the signature pages thereto, which provides for the issuance and sale, in a registered direct offering by the Company (the “Offering”), of (i) 156,250 shares of the Company’s common stock, par value $0.001 per share (the “common stock”), to certain of its direc…
Results of Operations and Financial Condition. The following information, including Exhibit 99.1, is being “furnished” in accordance with General Instruction B.2. of Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Ac…
Termination of a Material Definitive Agreement. In connection with entering the Sales Agreement, the Company delivered written notice to Jefferies indicating that it is terminating the Prior ATM Agreement, effective as of April 20, 2025. The Company filed with the SEC a prospectus supplement, which formed a part of the Registration Statement on Form S-3 (File No. 333-259783), declared effective by the SEC on November 8, 2021, relating to the offering of shares of Common Stock under the Prior…
Entry into a Material Definitive Agreement. On April 22, 2025, VolitionRx Limited (the “Company”) entered into a Capital On Demand TM Sales Agreement (the “Sales Agreement”) with JonesTrading Institutional Services LLC, acting as sales agent (the “Sales Agent”), pursuant to which the Company may offer and sell, from time to time, up to an aggregate of $7.5 million of shares (the “Shares”) of its common stock, $0.001 par value per share (the “Common Stock”), through the Sales Agent. The Sales…
Results of Operations and Financial Condition. The following information, including Exhibit 99.1, is being “furnished” in accordance with General Instruction B.2. of Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Ac…
Importance-ranked changes since the prior daily snapshot.
Management rose by 13.3 points (from 12.4 to 25.7).
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.